This market research report from Technavio segments the global liver diseases therapeutics market by disease indication (hepatitis, liver cirrhosis, and liver cancer), by type of molecule (biologics and small molecules), and by geography (Americas, EMEA, and APAC). Leading vendors analyzed in this market study are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, and Merck.
Technavio has released updated information on the healthcare therapeutics market, with the publication of its new market research report, global liver diseases therapeutics market. The global liver diseases therapeutics market is expected to grow at a CAGR of around 15% between 2015 and 2019, owing to the increased prevalence of liver cancer in developed countries and the expected entry of pipeline drugs into the market. The Americas dominate the global market for liver diseases therapeutics, followed by EMEA and the APAC regions. High medical unmet needs of the populace coupled with the augmented prevalence of liver diseases in the Americas are envisaged to account for its high market share of nearly 49% during the forecast period.
“Of late, pharmaceutical companies are developing several drugs, which are at different developmental stages. These drugs have better safety and efficacy profiles than the approved drugs. Moreover, these new medications are expected to reduce the rate of treatment withdrawal by patients Many pipeline molecules, such as Merck’s MK-5172 for treating hepatitis C and Celsion’s ThermoDox for treating primary liver cancer, are expected to be launched soon,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.
The hepatitis segment occupy more than 85% of the total market share. Hepatitis can be of types A, B, C, D, and E, among which hepatitis C is expected to have the highest prevalence during the forecast period. Viral infections, alcoholism, obesity, and diabetes are expected to be the most common causes of liver disease.
Segmentation of global liver diseases therapeutics market by disease
Source: Technavio Research
The key vendors in the global liver diseases therapeutics market are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, and Merck. This market is highly competitive due to the presence of numerous vendors who have develop branded, generic, and off-label drugs to cure liver diseases. Competition in this market is expected to increase during the forecast period due to the launch of pipeline drugs under different developmental stages.
A more detailed analysis is available in the Technavio report, Global Liver Diseases Therapeutics Market 2015-2019.
We can customize this reports by other regions and specific segments upon request.
Other Related Reports:
- Global Hospital Infection Therapeutics Market 2015-2019
- Global Plasma Therapeutics Market 2015-2019
- Global Cancer Pain Therapeutics Market 2015-2019
- Global Gaucher Disease Market 2015-2019
Further Reading:
